Bicycle Therapeutics plc (FRA:50BA)

Germany · Delayed Price · Currency is EUR

4.500

0.00 (0.00%)

At close: Mar 18, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Developing a Unique Class of Chemically Synthesized Medicines	72.59M	35.28M	26.98M	14.46M	11.70M
Developing a Unique Class of Chemically Synthesized Medicines Growth	105.77%	30.76%	86.52%	23.65%	12.58%
Total	72.59M	35.28M	26.98M	14.46M	11.70M
Total Growth	105.77%	30.76%	86.52%	23.65%	12.58%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United Kingdom	72.59M	35.28M	26.98M	14.46M	11.70M
United Kingdom Growth	105.77%	30.76%	86.52%	23.65%	12.58%
Total	72.59M	35.28M	26.98M	14.46M	11.70M
Total Growth	105.77%	30.76%	86.52%	23.65%	12.58%

Source: S&P Global Market Intelligence.